Intrathecal anti-CD20 efficiently depletes meningeal B cells in CNS autoimmunity

Clinical trials revealed that systemic administration of B-cell-depleting anti-CD20 antibodies can hold lesion formation in the early relapsing-remitting phase of multiple sclerosis (MS). Throughout the secondary-progressive (SP) course of MS, pathogenic B cells may, however, progressively replicate...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Lehmann-Horn, Klaus, Kinzel, Silke, Feldmann, Linda, Radelfahr, Florentine, Hemmer, Bernhard, Traffehn, Sarah, Bernard, Claude C A, Stadelmann, Christine, Brück, Wolfgang, Weber, Martin S
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BlackWell Publishing Ltd 2014
Konular:
Brief Communications
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4184778/
https://ncbi.nlm.nih.gov/pubmed/25356419
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acn3.71
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller